Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H17N7 |
Molecular Weight | 319.3638 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C2C(=NN(C3CCCC3)C2=NC=N1)C4=CC5=C(NC=C5)N=C4
InChI
InChIKey=NVRXTLZYXZNATH-UHFFFAOYSA-N
InChI=1S/C17H17N7/c18-15-13-14(11-7-10-5-6-19-16(10)20-8-11)23-24(12-3-1-2-4-12)17(13)22-9-21-15/h5-9,12H,1-4H2,(H,19,20)(H2,18,21,22)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18849971Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26235881 | https://www.ncbi.nlm.nih.gov/pubmed/26056008
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18849971
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26235881 | https://www.ncbi.nlm.nih.gov/pubmed/26056008
PP121 is a multitargeted dual receptor tyrosine kinases inhibitor. PP121 blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases. PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM. PP121 blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2041 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18849971 |
|||
Target ID: CHEMBL5914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26056008 |
30.0 nM [IC50] | ||
Target ID: CHEMBL279 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18849971 |
12.0 nM [IC50] | ||
Target ID: CHEMBL3234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18849971 |
8.0 nM [IC50] | ||
Target ID: CHEMBL2842 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18849971 |
13.0 nM [IC50] | ||
Target ID: CHEMBL2096980 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18849971 |
2.0 nM [IC50] | ||
Target ID: CHEMBL267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18849971 |
14.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26235881
30 mg/kg, oral gavage, daily, 30 d
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18849971
PP121 potently and dose-dependently (0.040 to 10 uM) blocked the phosphorylation of Akt, p70S6K and S6 in two glioblastoma cell lines, U87 and LN229. PP-121 at a low concentration of 40 nM inhibits Ret autophosphorylation in TT thyroid carcinoma cells that express the C634W oncogenic Ret mutant 35. PP-121 inhibits cell proliferation with IC50 of 50 nM in TT thyroid carcinoma cells. PP-121 inhibits cell proliferating stimulated only with VEGF with IC50 of 41 nM in human umbilical vein endothelial cells (HUVECs).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1092788-83-4
Created by
admin on Fri Dec 15 16:47:21 GMT 2023 , Edited by admin on Fri Dec 15 16:47:21 GMT 2023
|
PRIMARY | |||
|
DTXSID00648002
Created by
admin on Fri Dec 15 16:47:21 GMT 2023 , Edited by admin on Fri Dec 15 16:47:21 GMT 2023
|
PRIMARY | |||
|
DB08052
Created by
admin on Fri Dec 15 16:47:21 GMT 2023 , Edited by admin on Fri Dec 15 16:47:21 GMT 2023
|
PRIMARY | |||
|
24905142
Created by
admin on Fri Dec 15 16:47:21 GMT 2023 , Edited by admin on Fri Dec 15 16:47:21 GMT 2023
|
PRIMARY | |||
|
5B9VB06146
Created by
admin on Fri Dec 15 16:47:21 GMT 2023 , Edited by admin on Fri Dec 15 16:47:21 GMT 2023
|
PRIMARY | |||
|
50915
Created by
admin on Fri Dec 15 16:47:21 GMT 2023 , Edited by admin on Fri Dec 15 16:47:21 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD